Weiguang Biotech announced that it plans to sign a “technical cooperation contract for blood products” with partners, involving technical licensing and technology transfer for some blood products. The total cost is 16 million US dollars, equivalent to about 113 million yuan. The subject of the contract was technical licenses and services for the production of 6 types of blood products, which can be used at 4 production bases within the license area. The transaction does not constitute a major asset restructuring and is within the authority of the board of directors. Contract execution is expected to have a positive impact on operating results, but may be affected by factors such as personnel, facilities, and exchange rates.

Weiguang Biotech announced that it plans to sign a “technical cooperation contract for blood products” with partners, involving technical licensing and technology transfer for some blood products. The total cost is 16 million US dollars, equivalent to about 113 million yuan. The subject of the contract was technical licenses and services for the production of 6 types of blood products, which can be used at 4 production bases within the license area. The transaction does not constitute a major asset restructuring and is within the authority of the board of directors. Contract execution is expected to have a positive impact on operating results, but may be affected by factors such as personnel, facilities, and exchange rates.